Novel biological therapies for the treatment of diabetic foot ulcers

The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculat...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on biological therapy Vol. 17; no. 8; p. 979
Main Authors Adeghate, Jennifer, Nurulain, Syed, Tekes, Kornélia, Fehér, Erzsébet, Kalász, Huba, Adeghate, Ernest
Format Journal Article
LanguageEnglish
Published England 03.08.2017
Subjects
Biological Products - therapeutic use
Diabetic Foot - drug therapy
Diabetic Foot - etiology
Diabetic Foot - therapy
Diabetic Neuropathies - complications
Humans
Hypoglycemic Agents - therapeutic use
Immunomodulation
Intercellular Signaling Peptides and Proteins - therapeutic use
Stem Cell Transplantation
Urokinase-Type Plasminogen Activator - therapeutic use
Wound Healing
diabetic angiopathy
hyperglycemia
diabetic neuropathy
Diabetes mellitus
diabetic foot
therapy
ulcer
long-term complications
Online AccessGet more information

Cover

More Information
Summary:The number of people with diabetes mellitus (DM) is estimated to exceed 640 million by the year 2040. Diabetic foot ulcer (DFU) is a debilitating illness that affects more than 2% of DM patients. DFU is caused by DM-induced neural and vascular lesions leading to a reduced sensation and microcirculation. The increase in the prevalence of DFU has prompted researchers to find new therapies for the management of DFU. Areas covered: This review presents the current status of novel biological therapies used in the treatment of DFU. Literature information and data analysis were collected from PubMed, the website of the American Diabetes Association, and ClinicalTrials.gov. The keywords used in the search were: DM, DFU, complications of DM. Expert opinion: Many biological agents have been investigated in a bid to find an effective therapy for DFU. These include growth factors (platelet-derived growth factor, vascular endothelial growth factor etc), stem cells (epithelial progenitor-, adipose-derived stem cells etc), anti-diabetic drugs (insulin, exendin-4), herbs, urokinase, dalteparin, statins and bio-agents such as acid peptide matrix. Biological agents that can reduce hyperglycaemia, increase sensation, microcirculation and oxygenation and repair lost tissue are the most ideal for the treatment of DFU.
ISSN:1744-7682
DOI:10.1080/14712598.2017.1333596